Gandhar Oil posts robust FY26 profit

PAT soars 201%, EBITDA up 88% on strong PHPO demand & margin expansion

Biopharma firms must diversify CDMO partnerships to avoid costly delays: Shilpa Biologicals MD

Madhav Bhutada says overdependence on large CDMOs and delayed engagement can increase development costs by up to 40% and slow clinical progress

Jubilant Ingrevia delivers 14-quarter high revenue in Q4 FY26 as margins strengthen across biz

The company highlighted continued demand strength and pricing resilience despite global disruptions

Tecan launches direct India operations

The move signals a major expansion milestone for the Swiss laboratory automation company

Siegfried locks in CHF 200m bond deal as investors bet big on pharma outsourcing boom

The bonds, due June 15, 2030, were placed with Swiss investors under the joint lead of UBS and Zürcher Kantonalbank

Eli lilly goes all-in on vaccines with $3b+ triple acquisition push into infectious disease prevention

Lilly will acquire Curevo in a deal worth up to $1.5 billion in cash, including upfront and milestone-based payments.

Amgen appoints Madhur Sarin as Director – AI & Data Science COE

Sarin will focus on advancing scalable AI-driven platforms and strengthening the company’s global data science capabilities across healthcare and enterprise technology domains

Fredun FY26 profit jumps 60% as revenue hits Rs. 639 Cr

China greenlights Boehringer Ingelheim’s HERNEXEOS for aggressive lung cancer

The decision clears the drug as a monotherapy for adults with unresectable, locally advanced or metastatic non-small cell lung cancer

EMA backs conditional EU nod for Vijoice in rare life-threatening overgrowth disorder PROS

The company is expected to conduct further studies to confirm the long-term efficacy and safety of Vijoice in both adult and paediatric patients